Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the channel in its native membrane environment in open, closed and inactivated forms and the ensemble virtual screening accounting for conformational mobility in each of these states. Tentative binding pockets are considered inside the pore, in the gating region and in the allosteric locations to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9P0X4

UPID:
CAC1I_HUMAN

ALTERNATIVE NAMES:
Voltage-gated calcium channel subunit alpha Cav3.3

ALTERNATIVE UPACC:
Q9P0X4; B0QY12; B0QY13; B0QY14; O95504; Q5JZ88; Q7Z6S9; Q8NFX6; Q9NZC8; Q9UH15; Q9UH30; Q9ULU9; Q9UNE6

BACKGROUND:
Voltage-dependent T-type calcium channel subunit alpha-1I, alternatively known as Voltage-gated calcium channel subunit alpha Cav3.3, is crucial for the entry of calcium ions in excitable cells, affecting muscle contraction, neurotransmitter release, and cell motility. Its unique low-voltage activation feature is vital for neuron and cardiac cell pacemaking, as well as calcium signaling in various cell types, highlighting its broad physiological significance.

THERAPEUTIC SIGNIFICANCE:
The association of Voltage-dependent T-type calcium channel subunit alpha-1I with Neurodevelopmental disorder with speech impairment and with or without seizures underscores its therapeutic potential. Exploring this protein's function could lead to innovative treatments for diseases marked by seizures, developmental delays, and cognitive challenges.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.